Operating Income (Loss) in USD of Context Therapeutics Inc. from Q3 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Context Therapeutics Inc. quarterly/annual Operating Income (Loss) history and change rate from Q3 2020 to Q3 2025.
  • Context Therapeutics Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$10.6M, a 43.3% increase year-over-year.
  • Context Therapeutics Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$30.2M, a 7.18% increase year-over-year.
  • Context Therapeutics Inc. annual Operating Income (Loss) for 2024 was -$29.9M, a 19.3% decline from 2023.
  • Context Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$25.1M, a 63% decline from 2022.
  • Context Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$15.4M, a 46.1% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Context Therapeutics Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$30.2M -$10.6M +$8.09M +43.3% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025
Q2 2025 -$38.3M -$9.76M -$6.67M -216% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025
Q1 2025 -$31.6M -$5.53M -$1.71M -44.6% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025
Q4 2024 -$29.9M -$4.31M +$2.62M +37.8% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025
Q3 2024 -$32.5M -$18.7M -$12.5M -203% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025
Q2 2024 -$20M -$3.09M +$2.2M +41.6% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025
Q1 2024 -$22.2M -$3.82M +$2.84M +42.6% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025
Q4 2023 -$25.1M -$6.93M -$3.05M -78.6% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025
Q3 2023 -$22M -$6.18M -$2.13M -52.7% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024
Q2 2023 -$19.9M -$5.29M -$1.28M -32.1% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024
Q1 2023 -$18.6M -$6.67M -$3.22M -93.6% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024
Q4 2022 -$15.4M -$3.88M -$790K -25.6% 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024
Q3 2022 -$14.6M -$4.05M -$2.48M -158% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$12.1M -$4.01M +$1.02M +20.3% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023
Q1 2022 -$13.1M -$3.44M -$2.6M -310% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023
Q4 2021 -$10.5M -$3.09M 01 Oct 2021 31 Dec 2021 10-K 22 Mar 2023
Q3 2021 -$1.57M -$917K -141% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022
Q2 2021 -$5.03M 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022
Q1 2021 -$840K 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022
Q3 2020 -$651K 01 Jul 2020 30 Sep 2020 10-Q 02 Dec 2021

Context Therapeutics Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$29.9M -$4.85M -19.3% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025
2023 -$25.1M -$9.69M -63% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025
2022 -$15.4M -$4.86M -46.1% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024
2021 -$10.5M -$7.95M -309% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023
2020 -$2.57M 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.